Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $8.25 Million
Equities research analysts predict that Heron Therapeutics, Inc. (NASDAQ:HRTX) will announce $8.25 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heron Therapeutics’ earnings, with the lowest sales estimate coming in at $7.70 million and the highest estimate coming in at $8.80 million. The firm is expected to issue its next earnings results on Tuesday, November 14th.
According to Zacks, analysts expect that Heron Therapeutics will report full year sales of $8.25 million for the current financial year. For the next year, analysts anticipate that the firm will post sales of $83.90 million per share. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analyst estimates of $4.53 million.
A number of research firms have recently weighed in on HRTX. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 18th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, August 10th. Finally, Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Heron Therapeutics presently has an average rating of “Buy” and a consensus price target of $29.25.
Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in shares of Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,098 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Heron Therapeutics in the 1st quarter valued at approximately $161,000. Quantbot Technologies LP raised its stake in shares of Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares in the last quarter. Old West Investment Management LLC bought a new position in shares of Heron Therapeutics in the 1st quarter valued at approximately $206,000. Finally, HighTower Advisors LLC raised its stake in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares in the last quarter.
Shares of Heron Therapeutics (HRTX) opened at 14.70 on Friday. The firm’s market cap is $795.83 million. The company’s 50-day moving average is $15.90 and its 200-day moving average is $14.95. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $20.85.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Heron Therapeutics, Inc. (HRTX) Will Post Quarterly Sales of $8.25 Million” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/brokerages-anticipate-heron-therapeutics-inc-hrtx-will-post-quarterly-sales-of-8-25-million-2.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.